-
Abstract Number: L01
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
-
Abstract Number: L02
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
-
Abstract Number: L03
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
-
Abstract Number: L04
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
-
Abstract Number: L05
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
-
Abstract Number: L06
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
-
Abstract Number: L07
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
-
Abstract Number: L08
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
-
Abstract Number: L09
Comparative Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors: A Cohort Study of Rheumatoid Arthritis Patients
-
Abstract Number: L10
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
-
Abstract Number: L11
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
-
Abstract Number: L12
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
-
Abstract Number: L13
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
-
Abstract Number: L14
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
-
Abstract Number: L15
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
- 1
- 2
- 3
- …
- 202
- Next Page »